New views on the hypothesis of respiratory cancer risk from soluble nickel exposure; and reconsideration of this risk's historical sources in nickel refineries.
BACKGROUND
While epidemiological methods have grown in sophistication during the 20th century, their application in historical occupational (and environmental) health research has also led to a corresponding growth in uncertainty in the validity and reliability of the attribution of risk in the resulting studies, particularly where study periods extend back in time to the immediate postwar era (1945-70) when exposure measurements were sporadic, unsystematically collected and primitive in technique; and, more so, to the pre-WWII era (when exposure data were essentially non-existent). These uncertainties propagate with animal studies that are designed to confirm the carcinogenicity by inhalation exposure of a chemical putatively responsible for historical workplace cancers since exact exposure conditions were never well characterized. In this report, we present a weight of scientific evidence examination of the human and toxicological evidence to show that soluble nickel is not carcinogenic; and, furthermore, that the carcinogenic potencies previously assigned by regulators to sulphidic and oxidic nickel compounds for the purposes of developing occupational exposure limits have likely been overestimated.


METHODS
Published, file and archival evidence covering the pertinent epidemiology, biostatistics, confounding factors, toxicology, industrial hygiene and exposure factors, and other risky exposures were examined to evaluate the soluble nickel carcinogenicity hypothesis; and the likely contribution of a competing workplace carcinogen (arsenic) on sulphidic and oxidic nickel risk estimates.


RESULTS
Sharp contrasts in available land area and topography, and consequent intensity of production and refinery process layouts, likely account for differences in nickel species exposures in the Kristiansand (KNR) and Port Colborne (PCNR) refineries. These differences indicate mixed sulphidic and oxidic nickel and arsenic exposures in KNR's historical electrolysis department that were previously overlooked in favour of only soluble nickel exposure; and the absence of comparable insoluble nickel exposures in PCNR's tankhouse, a finding that is consistent with the absence of respiratory cancer risk there. The most recent KNR evidence linking soluble nickel with lung cancer risk arose in a reconfiguration of KNR's historical exposures. But the resulting job exposure matrix lacks an objective, protocol-driven rationale that could provide a valid and reliable basis for analyzing the relationship of KNR lung cancer risk with any nickel species. Evidence of significant arsenic exposure during the processing step in the Clydach refinery's hydrometallurgy department in the 1902-1934 time period likely accounts for most of the elevated respiratory cancer risk observed at that time. An understanding of the mechanism for nickel carcinogenicity remains an elusive goal of toxicological research; as does its capacity to confirm the human health evidence on this subject with animal studies.


CONCLUSIONS
Epidemiological methods have failed to accurately identify the source(s) of observed lung cancer risk in at least one nickel refinery (KNR). This failure, together with the negative long-term animal inhalation studies on soluble nickel and other toxicological evidence, strongly suggest that the designation of soluble nickel as carcinogenic should be reconsidered, and that the true causes of historical lung cancer risk at certain nickel refineries lie in other exposures, including insoluble nickel compounds, arsenic, sulphuric acid mists and smoking.
Heller
James G
JG
James G. Heller Consulting Inc., 1 Berney Crescent, Toronto ON, M4G 3G4, Canada.|Dalla Lana School of Public Health, University of Toronto, 6th Floor, Health Sciences Building, 155 College Street, Toronto ON, M5T 3M7, Canada.
Thornhill
Philip G
PG
Metallurgical Research, Falconbridge Ltd, Toronto ON, Canada.
Conard
Bruce R
BR
Environmental and Health Sciences, Inco Ltd, Toronto, ON, Canada.|BR Conard Consulting, Inc., 153 Balsam Drive, Oakville ON, L6J 3X4, Canada.
Br J Ind Med. 1958 Oct;15(4):224-34
13596544
Int J Cancer. 1973 Jul 15;12(1):32-41
4790709
Int Arch Occup Environ Health. 1998 Jun;71(4):245-50
9638480
Br J Ind Med. 1958 Oct;15(4):217-23
13596543
Am J Epidemiol. 2002 Dec 15;156(12):1123-32
12480657
Int J Cancer. 1982 Dec 15;30(6):681-5
7160938
Occup Environ Med. 1996 Oct;53(10):714-7
8943838
Risk Anal. 1996 Oct;16(5):613-7
8962512
Toxicol Ind Health. 1989 Dec;5(6):975-93
2626765
Int Arch Occup Environ Health. 1992;63(8):547-51
1587630
Natl Toxicol Program Tech Rep Ser. 1996 Jul;453:1-365
12594522
Toxicol Ind Health. 1991 Jul;7(4):277-94
1776158
IARC Sci Publ. 1984;(53):37-46
6532988
J Environ Monit. 2003 Apr;5(2):190-7
12729252
Scand J Work Environ Health. 1990 Feb;16(1 Spec No):1-82
2185539
Br J Cancer. 1970 Dec;24(4):623-32
5503591
Environ Health Perspect. 2002 Oct;110 Suppl 5:841-4
12426143
Science. 1990 Aug 31;249(4972):970-1
2136249
Analyst. 1998 Apr;123(4):687-9
9684402
Occup Environ Med. 2005 Feb;62(2):80-5
15657188
Natl Toxicol Program Tech Rep Ser. 1996 Jul;451:1-381
12594524
Toxicol Ind Health. 1989 Dec;5(6):957-74
2626764
Br J Cancer. 1947 Dec;1(4):383-91
18906316
Occup Environ Med. 2006 May;63(5):365-6
16621856
Br J Ind Med. 1981 Nov;38(4):327-33
7317295
Risk Anal. 1992 Dec;12(4):525-33
1480798
Scand J Work Environ Health. 2000 Aug;26(4):338-45
10994800
Toxicol Appl Pharmacol. 1997 Mar;143(1):152-66
9073603
Scand J Work Environ Health. 2006 Feb;32(1):41-50
16539171
Cancer Res. 1994 Aug 1;54(15):4045-51
8033135
Natl Toxicol Program Tech Rep Ser. 1996 Jul;454:1-380
12587012
Am J Public Health. 2005;95 Suppl 1:S129-36
16030328
J Environ Monit. 1999 Dec;1(6):557-62
11529189
Epidemiology. 2005 Mar;16(2):146-54
15703528
Acta Obstet Gynecol Scand. 2004 Jan;83(1):58-69
14678087
Occup Environ Med. 1996 Oct;53(10):708-13
8943837
Fundam Appl Toxicol. 1995 Dec;28(2):232-44
8835233
Regul Toxicol Pharmacol. 2003 Apr;37(2):173-90
12726752
J Natl Cancer Inst. 1986 Oct;77(4):841-8
3463817
Int J Circumpolar Health. 2004 Mar;63(1):39-60
15139240
Toxicol Appl Pharmacol. 2008 Dec 1;233(2):262-75
18822311
Br J Cancer. 1949 Sep;3(3):384-6
15394415
J Environ Monit. 2008 Apr;10(4):532-40
18385875
Br J Ind Med. 1977 May;34(2):102-5
871439
Regul Toxicol Pharmacol. 2005 Mar;41(2):128-33
15698536